|
|
Post by od on Sept 11, 2016 11:23:09 GMT -5
What we should ask ourselves is why didn't Mannkind have a presence at these venues if these are the prescribers that Mannkind's sales force are supposed to be targeting? Seems a little absurd. Industry has no business having a presence at a Continuing Medical Education event. Promulgating data is usually the purview of pharmaceutical company Medical Affairs department. |
|
|
|
Post by mannmade on Sept 11, 2016 11:55:34 GMT -5
It simply may not have been on their radar. It coincides with the response I got when discussing AFREZZa with a new diabetologist. She had an article saying that AFREZZA actually caused more hypo events. I have sent a note to mike about both of these events.
|
|
|
|
Post by od on Sept 11, 2016 12:06:58 GMT -5
It simply may not have been on their radar. It coincides with the response I got when discussing AFREZZa with a new diabetologist. She had an article saying that AFREZZA actually caused more hypo events. I have sent a note to mike about this. MM - I don't disagree but, if the session saxcmann was referencing was Diabetes Therapeutics: From New Insulins to Incretins, it was presented by Robert S. Zimmerman, MD, Director, Cleveland Clinic Diabetes Center; Vice Chairman, Department of Endocrinology, Diabetes and Metabolism, Endocrinology and Metabolism Institute, Cleveland Clinic. Dr. Zimmerman is a respected opinion leader based at a center of excellence. New data needs to be in front of opinion leaders as soon as it is released. |
|
